Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma

Video

In Partnership With:

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

The phase II study randomized patients to receive the combination of the two immunotherapy agents to ipilimumab alone. Researchers sought to determine the safety profile and progression-free survival (PFS) of the two arms.

Data showed a significant improvement in PFS in the combination arm versus the single-agent arm. Researchers also observed a complete remission rate in 22% of patients receiving the combination. However, autoimmune toxicities were higher in the combination arm versus the ipilimumab alone arm, and should be treated aggressively.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD